OncLive TV

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Katherine L. Nathanson, MD, discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Rami Komrokji, MD, discusses how consensus guidelines could address unanswered questions regarding the management of high-risk MDS.

Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses the safety profile of daraxonrasib in patients with KRAS-mutated pancreatic ductal adenocarcinoma

Alberto Chiappori, MD, discusses the selection between frontline treatment options, including ensartinib, in ALK-positive non–small cell lung cancer.

Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.

Aditya Bardia, MD, MPH, FASCO, discusses the need for widespread HER2 testing in patients with HER2-low and -ultralow metastatic breast cancer.

Marwan G. Fakih, MD, emphasizes the need for next-generation sequencing in colorectal cancer to inform treatment sequencing.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Icro Meattini, ​MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy​ addresses unmet needs for patients with metastatic ESCC.

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.